Aflibercept 18 November 2024 | EU | Approval Alert: Samsung Bioepis/Biogen’s Aflibercept Biosimilar Approved in EU On...

Aflibercept 18 November 2024 | EU | Approval Alert: Samsung Bioepis/Biogen’s Aflibercept Biosimilar Approved in EU On...
As patent proceedings involve substantial legal expenses, parties typically employ various mechanisms to optimise cost recovery, often by issuing Calderbank letters as well as formal Notices of Offer under the Federal Court Rules, which place the receiving party at risk of indemnity costs orders should the other party receive a more favourable judgment than the terms proposed in the offer.
Delegate Wagg of the Australian Patent Office has ruled in favour of Dana-Farber Cancer Institute, Inc. and The General Hospital Corporation (the Applicants) in “straw person” opposition proceedings brought by QIP Nominees Pty Ltd (QIP), a company within the QANTM intellectual property group.
Aflibercept 15 November 2024 | EU | Sandoz Aflibercept Biosimilars EU Approved & Formycon/Klinge Biosims...
Aflibercept 30 October 2024 | US | Amgen Launches Aflibercept in the US, Prepares to Launch Ustekinumab &...
Benralizumab 28 October 2024 | EU | New Indication Alert: AstraZeneca’s Fasenra® (Benralizumab) EU-Approved for EGPA...
Aflibercept 23 October 2024 | Biocon Switching Study for Aflibercept Confirms Safety & Efficacy On 23 October...
In a recent decision of the Australian Patent Office, Delegate McCaffery has ruled on opposition proceedings between ResMed Pty Ltd (ResMed) and Fisher & Paykel Healthcare Limited (Fisher & Paykel). The proceedings concerned six patent applications relating to patient interfaces for delivering breathing gases, with specific focus on nasal seals for continuous positive airway pressure (CPAP) therapy.
Aflibercept 18 October 2024 | Regeneron Announces 3-Year Results for High Dose Eylea® (Aflibercept) On 18 October...
Aflibercept 8 October 2024 | AU | Bayer’s High Dose Eylea® (Aflibercept) PFS Approved in Australia On 8 October 2024,...
On 18 June 2024, Justice Burley delivered a decision regarding documentary discovery in the long running dispute between Pfizer (Pfizer Ireland Pharmaceuticals and Pfizer Australia) and four of its competitors over AU2005280034 for the “Production of polypeptides” (the Pfizer Patent).
On 18 June 2024, Justice Burley delivered a decision regarding documentary discovery in the long running dispute between Pfizer (Pfizer Ireland Pharmaceuticals and Pfizer Australia) and four of its competitors over AU2005280034 for the “Production of polypeptides” (the Pfizer Patent).
On 18 June 2024, Justice Burley delivered a decision regarding documentary discovery in the long running dispute between Pfizer (Pfizer Ireland Pharmaceuticals and Pfizer Australia) and four of its competitors over AU2005280034 for the “Production of polypeptides” (the Pfizer Patent).
Aflibercept 23 September 2024 | Positive 52-Week, Ph 3 Results for Celltrion’s Aflibercept Biosimilar On 23 September...
Aflibercept 19 September 2024 | EU | Sandoz & Samsung Bioepis/Biogen Aflibercept Biosimilars Recommended in Europe...
Aflibercept 13 September 2024 | KR | Alteogen Submits Application for Biosimilar Aflibercept in Korea On 13 September...